Taft Pharmaceutical and Life Sciences attorneys, Roshan Shrestha, Ph.D. and Stephen Auten will present “Recent Cases and Trends in U.S. Litigation,” at 9:30 a.m. Indian Standard Time (IST) during the Global Dialogue on Intellectual Property Strategies webinar on Oct. 8.
The webinar will cover important Federal Circuit and District Court decisions on topics such as: Section viii Carve Outs - GSK v. Teva, Reverse Payment Settlement – Impax v. FTC, Obviousness – UCB v. Actavis, Objective Indicia of Nonobviousness – Chemours v. Daikan and Amarin v. Hikma, ANDA legal fees Tax Deductible – Mylan v. IRS, Venue – Valeant v. Mylan.
Shrestha focuses his practice on all aspects of intellectual property law, including patent litigation, prosecution and opinion work in the chemical, pharmaceutical and electronic material arts. He has a broad scope of pharmaceutical and life sciences capabilities, including Hatch-Waxman litigation and inter partes review proceedings at the USPTO. Shrestha has been recognized by Super Lawyers® as a Rising Star since 2014. In 2016, he was named to Law Bulletin’s “40 Illinois Attorneys Under 40 to Watch.” Before practicing law, Shrestha was a research scientist at Los Alamos National Laboratory in New Mexico, where his investigation on materials for hydrogen storage technology received several patents.
Auten is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators and others on his LinkedIn blog "Hatch Waxman ANDA Litigation Forum," which has more than 11,000 members worldwide. He currently represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation, and biosimilar market opportunities.
For more information or to register to attend, click here. You can also contact Vanessa Lobo at +91 876-741-7018 or by email.